FITC anti-human CD8a Antibody
- 产品名称：
- FITC anti-human CD8a Antibody
- 产品类别：
- 抗体
- 产品编号：
- 301005
- 产品应用：
- 301005
- Verified Reactivity
- Human, Cynomolgus, Rhesus
- Reported Reactivity
- Chimpanzee, Baboon, Pigtailed Macaque, Sooty Mangabey
- Antibody Type
- Monoclonal
- Host Species
- Mouse
- Formulation
- ?g size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
test sizes: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA). - Preparation
- The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
- Concentration
- ?g sizes: 0.5 mg/mLtest sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the ?g size, the suggested use of this reagent is ≤1.0 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application. For flow cytometric staining using the test sizes, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.
- Excitation Laser
- Blue Laser (488 nm)
- Application Notes
The RPA-T8 antibody does not block the binding of HIT8a antibody to CD8a. Additional reported applications of this antibody (for the relevant formats) include: immunohistochemical staining of paraformaldehyde-fixed frozen sections3 and costimulation of T cell responses4. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. Nos. 301073 & 301074).
- Application References
(PubMed link indicates BioLegend citation) -
- Knapp W, et al. Eds. 1989. Leucocyte Typing IV. Oxford University Press. New York.
- Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
- Mack CL, et al. 2004. Pediatr. Res. 56:79. (IHC)
- Magidovich E, et al. 2007. P. Natl. Acad. Sci. USA 104:13022.
- Thakarl D, et al. 2008.J. immunol. 180:7431. PubMed
- Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed
- Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
- Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
- Rout N, et al. 2010. PLoS One 5:e9787. (FC)
- Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
- Product Citations
-
- Wenthe J, et al. 2021. Cancer Immunology Immunotherapy. . PubMed
- Poonia B, Pauza C 2014. PLoS One. 9:88884. PubMed
- Luo X, et al. 2020. Front Immunol. 11:623. PubMed
- Roberts A, et al. 2021. Sci Rep. 11:4030. PubMed
- Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
- Zhang Y, et al. 2022. Front Immunol. 12:799206. PubMed
- Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
- Shi Z, et al. 2009. Eur J Immunol. 39:2106. PubMed
- Costa-Martins AG, et al. 2021. Cell Rep Med. 2:100465. PubMed
- Kan S, et al. 2020. Int J Oncol. 57:1047. PubMed
- Tian X, et al. 2021. Annals of Translational Medicine. 9(9):781. PubMed
- Zhang D, et al. 2020. Oncoimmunology. 9:1744921. PubMed
- Haruna M, et al. 2020. Biol Pharm Bull. 43:399. PubMed
- Chandran P, et al. 2014. J Leukoc Biol. 96:633. PubMed
- Vaurs J, et al. 2021. Sci Rep. 11:17234. PubMed
- Jung JH, et al. 2021. Nat Commun. 12:4043. PubMed
- Nakasone H, et al. 2021. Commun Biol. 4:1177. PubMed
- Bartok O, et al. 2020. Nature. . PubMed
- Castro I, et al. 2016. J Virol. 90: 5280 - 5291. PubMed
- Wallstabe L et al. 2019. JCI Insight. 4(18) pii: 126345. PubMed
- Port JR, et al. 2020. J Virol. 94:. PubMed
- Termini J, et al. 2017. J Virol. 10.1128/JVI.00950-17. PubMed
- Louka E, et al. 2021. Journal of Experimental Medicine. 218(2):. PubMed
- Rodriguez-Meira A, et al. 2020. STAR Protoc. 1:100125. PubMed
- Georg P, et al. 2022. Cell. 185:493. PubMed
- Landgraf KE, et al. 2020. Commun Biol. 0.330555556. PubMed
- Tamai Y, et al. 2013. J Immunol. 190:4382. PubMed
- Danzer H, et al. 2020. Elife. 9:00. PubMed
- Sashihara J, et al. 2011. PLoS One. 6:e1002308. PubMed
- Franchini DM et al. 2019. Cell reports. 26(1):94-107 . PubMed
- Rodriguez‐Meira A et al. 2019. Molecular cell. 73(6):1292-1305 . PubMed
- RRID
- AB_314123 (BioLegend Cat. No. 301005) AB_314124 (BioLegend Cat. No. 301006) AB_2564165 (BioLegend Cat. No. 301060) AB_2562055 (BioLegend Cat. No. 301050)
- Structure
- Ig superfamily, homodimer or heterodimer with CD8β, 32-34 kD
- Distribution
-
Majority of thymocytes, T cell subset, NK cells
- Function
- MHC class I co-receptor, thymic differentiation, T cell activation
- Ligand/Receptor
- MHC Class I molecules
- Cell Type
- Dendritic cells, NK cells, T cells, Thymocytes, Tregs
- Biology Area
- Immunology
- Molecular Family
- CD Molecules
- Antigen References
-
1. Barclay N, et al. 1993. The Leucocyte Antigen FactsBook. Academic Press Inc. San Diego.
- Gene ID
- 925 View all products for this Gene ID
- UniProt
- View information about CD8a on UniProt.org
